Mesna, short for 2-Mercaptoethane sulfonic acid sodium salt, is a medication primarily used to prevent or minimize the adverse effects associated with the administration of certain chemotherapy drugs, particularly cyclophosphamide and ifosfamide. These chemotherapeutics can cause hemorrhagic cystitis, a painful and potentially serious inflammation of the bladder, due to their metabolites forming toxic byproducts. It acts as a uroprotectant by providing a sulfur donor group that reacts with these toxic metabolites, converting them into inactive, water-soluble forms that are readily excreted through urine, thereby reducing their bladder toxicity. It is commonly administered intravenously or orally, depending on the treatment regimen and patient's condition.
In addition to its protective role, it also helps maintain the efficacy of the chemotherapy by preventing the premature inactivation of the drugs outside the target tissues. This dual action makes it an essential adjunct in many cancer treatment protocols.
While generally well-tolerated, it may cause mild side effects such as nausea, vomiting, and diarrhea. More severe reactions, although rare, can include allergic responses and alterations in blood chemistry. Close monitoring and adherence to prescribed dosages are crucial to ensure patient safety and optimal treatment outcomes.
In summary, mesna is a vital medication in the management of chemotherapy-induced bladder toxicity, enhancing the safety and tolerability of essential cancer treatments.
|
|
|
| Chemical Formula | C2H6O3S2 |
| Exact Mass | 141.98 |
| Molecular Weight | 142.19 |
| m/z | 141.98 (100.0%), 143.97 (9.0%), 142.98 (2.2%), 142.98 (1.6%) |
| Elemental Analysis | C, 16.89; H, 4.25; O, 33.76; S, 45.10 |
Chemotherapy Protectant
Chemical Structure: Mesna is a thiol compound, which, upon metabolism, converts to di-mesna and is excreted by the kidneys. Once it reaches the bladder, it is reactivated and binds to acrylaldehyde, facilitating effective excretion.
Mechanism of Protection: In the bloodstream, it is initially inactivated to form the disulfide. However, when it is filtered by the kidneys and excreted into the bladder, it is reactivated. The free sulfhydryl groups produced bind to acrylaldehyde in the bladder, thereby protecting the bladder mucosa from damage and preventing the occurrence of hemorrhagic cystitis.
Prevention of Hemorrhagic Cystitis
Primarily used to prevent hemorrhagic cystitis induced by high-dose cyclophosphamide or ifosfamide chemotherapy. By binding to toxic metabolites in the bladder, it reduces bladder toxicity and protects bladder function.
Dosage and Administration
The dosage should be calculated based on the total daily dose of ifosfamide. Typically, the recommended dosage is equivalent to 60% of the total daily dose of ifosfamide. It is administered in three doses: 15 minutes before each dose of ifosfamide, and 4 hours and 8 hours after each dose. When used with continuous infusion of ifosfamide, a bolus dose equivalent to 20% of the total ifosfamide dose may be given, followed by a constant infusion equivalent to 40% of the ifosfamide dose, infused over 12 to 24 hours after the completion of ifosfamide administration.
Administration Notes
- Dilution and Administration Route: Can be diluted in 5% glucose injection, 0.45% sodium chloride injection, 0.9% sodium chloride injection, or lactate Ringer's injection to obtain a final concentration of 20 mg/mL for intravenous infusion. It can also be administered orally as 400 mg tablets, although the tablets have a strong unpleasant sulfur odor and taste, and are usually recommended to be taken with juice or food.
- Patient Instructions: Patients should be instructed to drink at least 2 liters of fluid per day and to keep their bladder empty as much as possible to enhance the excretion of toxic metabolites.
|
|
|
About HC
Hemorrhagic cystitis (HC) is a medical condition characterized by inflammation and bleeding in the bladder. This inflammation can lead to the formation of ulcers, blood clots, and even obstruction of the bladder outlet, causing significant discomfort and potential urinary tract complications.
The symptoms of hemorrhagic cystitis typically include pain or discomfort in the lower abdomen, frequent urination, urgency to urinate, and sometimes the presence of blood in the urine (hematuria). In severe cases, the urine may appear bright red, indicating significant bleeding. The condition can range from mild to severe, and its severity often dictates the treatment approach.
Hemorrhagic cystitis can be caused by a variety of factors, including infections, radiation therapy, certain medications (such as cyclophosphamide and ifosfamide, which are used in chemotherapy for cancer treatment), and exposure to toxic chemicals. In some cases, the exact cause may remain unknown.
Diagnosis of hemorrhagic cystitis involves a thorough medical history and physical examination, along with urine tests and imaging studies such as cystoscopy (a procedure that uses a small camera to view the inside of the bladder) and ultrasound.
Treatment of hemorrhagic cystitis depends on the underlying cause and severity of the symptoms. In mild cases, it may involve increasing fluid intake, avoiding irritants, and using pain relievers. More severe cases may require bladder irrigation (washing out the bladder with a saline solution), medications to control bleeding and inflammation, or even surgical intervention in rare cases.
It is important to seek medical attention if you experience symptoms of hemorrhagic cystitis, as early diagnosis and treatment can help prevent complications and improve outcomes. With appropriate care, most patients with hemorrhagic cystitis can experience symptom relief and return to normal bladder function.
potential clinical utilities
The thiol group endows it with antioxidant properties, making it a promising candidate for treating conditions involving oxidative stress. Studies suggest its efficacy in mitigating radiation-induced tissue damage, particularly in the bladder and rectum, by scavenging free radicals and reducing inflammation.
In addition, it demonstrates anti-inflammatory activities, hinting at its potential use in inflammatory bowel diseases, such as ulcerative colitis, by modulating immune responses and reducing tissue damage. Its ability to protect against ischemia-reperfusion injury also makes it a potential therapeutic option in conditions like myocardial infarction and stroke, where restoring blood flow can paradoxically harm tissues.
Moreover, the ability to bind and detoxify aldehydes may extend its application to the management of certain toxic exposures and metabolic disorders. Research is ongoing to explore its use in conditions like uremic pruritus, where it could alleviate itching by scavenging uremic toxins.
Furthermore, the cytoprotective effects are being investigated for the prevention of chemotherapy-induced peripheral neuropathy, aiming to preserve nerve function and improve patient quality of life.
In summary, the multifaceted properties position it as a versatile therapeutic with potential across diverse clinical scenarios, from mitigating radiation damage to treating inflammatory conditions and metabolic disorders. Ongoing research continues to unravel its full therapeutic potential.
Mesna, also known as Sodium 2-mercaptoethanesulfonate, is a compound with significant biological activity and pharmacological properties. Its CAS number is 19767-45-4.
In terms of biological activity, it acts as an antioxidant with cell-protective effects. It has been widely utilized as a systemic protective agent against chemotherapy toxicity. It can reduce the concentrations of H2O2, HOCl, and OH• in a dose-dependent manner, with IC50 values of 32, 21, and 305 μM respectively in cell-free experiments. This indicates its ability to scavenge reactive oxygen species and protect cells from oxidative stress.
Pharmacologically, it is primarily used to decrease the incidence of hemorrhagic cystitis associated with certain chemotherapy agents, such as cyclophosphamide. It achieves this by protecting the urothelium and bladder from damage caused by these toxic agents. Additionally, it has shown protective effects in animal models against traumatic brain injury and cisplatin-induced ovarian damage, further demonstrating its broad spectrum of pharmacological activities.
In summary, it is a versatile compound with potent antioxidant and cell-protective properties. Its ability to scavenge reactive oxygen species and protect cells from damage makes it a valuable tool in the treatment of chemotherapy-induced toxicities, particularly hemorrhagic cystitis. With further research, mesna may find additional applications in the medical field.
Mesna represents a critical advancement in the management of chemotherapy-induced hemorrhagic cystitis, offering a safe and effective means of preventing this debilitating complication in patients receiving oxazaphosphorine chemotherapeutic agents. Its unique mechanism of action, favorable pharmacokinetic profile, and proven efficacy in clinical trials have solidified its position as a standard of care in oncology practice. Moreover, its potential role in preventing ifosfamide-induced encephalopathy and other chemotherapy-related complications opens new avenues for its clinical application.
As our understanding of mesna's pharmacological properties and clinical applications continues to evolve, ongoing research will undoubtedly uncover additional indications and refine its role in the management of chemotherapy-induced toxicities. With its excellent safety profile and minimal drug interaction potential, mesna is poised to remain a cornerstone of supportive care in oncology for years to come.
Frequently Asked Questions
Is mesna chemotherapy or immunotherapy?
+
-
What is this medication? MESNA (MES na) reduces the risk of bleeding in the bladder caused by ifosfamide, a type of chemotherapy. It works by protecting your bladder from substances in the urine that may irritate it.
Is mesna safe to take?
+
-
This medication may cause serious skin reactions. They can happen weeks to months after starting the medication. Contact your care team right away if you notice fevers or flu-like symptoms with a rash. The rash may be red or purple and then turn into blisters or peeling of the skin.
What chemo needs mesna?
+
-
People being treated with ifosfamide will always have mesna. Cyclophosphamide only causes bleeding from the bladder when it is given in high doses. Most people who have treatment with cyclophosphamide do not have a high dose. This means they will not need mesna.
What is the 7 day rule in chemotherapy?
+
-
The 7-day rule for chemotherapy is designed to do a few things to get rid of cancer and make treatment easier on your body: It helps maintain consistent pressure on cancer cells by ensuring a balanced treatment that can interrupt the growth cycle. It reduces the toxicity of treatment and can help minimize side effects.
What are good signs that chemo is working?
+
-
You might notice an improvement in cancer symptoms, such as less pain, reduced lymph node swelling, and improved energy levels. If you use topical chemotherapy on skin lesions, the area might feel irritated and look red and swollen for the first few weeks. These are all signs that chemotherapy is working.
Hot Tags: mesna cas 19767-45-4, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, 4 bromo 1 1 4 1 terphenyl, 2 bromo N 4 chlorophenyl aniline, 2 chloro 4 dibenzo b d furan 1 yl 6 phenyl 1 3 5 triazine, Dibenzofuran 1 bromo 4 chloro , tris base powder, N5 dibenzo b d thiophen 3 yl 7 7 dimethyl N5 N9 N9 triphenyl 7H benzo c fluorene 5 9 diamine